Mr. Sunny Kumar | Nanobiotechnology | Young Scientist Award
Researcher, CSIR-Indian Institute Of Chemical Biology, India
Mr. Sunny Kumar is an emerging researcher in cancer biology and nanomedicine, recognized for his interdisciplinary contributions that bridge molecular oncology, tumor microenvironment studies, and nanotechnology-driven therapeutics. With an h-index of 6, 11 publications, and 148 citations (as indexed in Scopus), his research reflects both productivity and impact within translational cancer science. His primary research focuses on elucidating the molecular mechanisms underlying glioma, colorectal, and breast cancer progression, emphasizing protein quality control systems such as the ubiquitin-proteasome system and their regulatory influence on oncogenic signaling. Mr. Sunny Kumar has explored novel therapeutic targets like E3 ligases (CHIP), PD-1/PD-L1 pathways, and HAUSP-MDM2 axes, offering valuable insights for cancer immunotherapy and personalized treatment strategies. In addition to mechanistic studies, Mr. Sunny Kumar integrates nanobiotechnology and drug delivery innovation, developing nanoparticle-based formulations capable of crossing the blood–brain barrier for targeted glioma therapy. His research on dual-drug nanotherapeutics and carbon nanotube-based diagnostic platforms has contributed to the advancement of precision medicine approaches for difficult-to-treat cancers. He has published extensively as first or corresponding author in high-impact journals such as Genes & Diseases (IF 9.4), BBA-Molecular Cell Research (IF 3.7), International Journal of Pharmaceutics (IF 5.2), and Journal of Medicinal Chemistry (IF 6.8). His scholarly output also includes multiple book chapters with Springer and Taylor & Francis, covering cancer proteomics, personalized therapy, and nanotherapeutics. Mr. Sunny Kumar serves as a peer reviewer for reputed journals, including BBA–Reviews on Cancer and Experimental Cell Research, further demonstrating his engagement in the scientific community. His research exhibits a robust methodological framework, integrating cell and molecular biology, bioinformatics, animal models, and nanocarrier engineering. Collectively, Mr. Sunny Kumar’s scientific endeavors underscore a commitment to next-generation cancer therapeutics, aiming to translate molecular discoveries into clinically viable nanomedicine solutions for precision oncology.
Featured Publications
1. Kumar, S., Chatterjee, M., Ghosh, P., Ganguly, K. K., Basu, M., & Ghosh, M. K. (2023). Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes & Diseases, 10(4), 1318–1350.
2. Kumar, S., Basu, M., & Ghosh, M. K. (2022). Chaperone-assisted E3 ligase CHIP: A double agent in cancer. Genes & Diseases, 9(6), 1521–1555.
3. Kumar, S., Basu, M., Ghosh, P., Ansari, A., & Ghosh, M. K. (2023). COVID‐19: Clinical status of vaccine development to date. British Journal of Clinical Pharmacology, 89(1), 114–149.
4. Kumar, S., Basu, M., Ghosh, P., Pal, U., & Ghosh, M. K. (2023). COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery. Genes & Diseases, 10(4), 1402–1428.
5. Ghosh, M. K., Kumar, S., Ganguly, K. K., Ghosh, P., Tabassum, S., Basu, B., & Basu, M. (2023). COVID-19 and cancer: Insights into their association and influence on genetic and epigenetic landscape. Epigenomics, 15(4), 227–248.